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LETTERS TO THE EDITORA Case of Pancreatic Ductal
Adenocarcinoma Arising
From Atypical Flat LesionsTo the Editor:A typical flat lesions (AFLs) in the pan-creas have been suggested a potential
precursor to pancreatic ductal adenocarcinoma
via acinar-to-ductal metaplasia (ADM) in
mouse model studies. Still, the role of AFLs
in human pancreatic cancer is unknown. Here,
we present a case ofKRAS-mutated pancre-
atic ductal adenocarcinoma arising from
AFLs based on clear histopathological find-
ings. This incidental finding highlights the
need for further investigation of the prevalence
and role of AFLs in human pancreatic duc-
tal adenocarcinoma (PDAC) development.
CASE REPORT
A woman around 70 years old presented
with abdominal pain and jaundice. No solid
tumor was found on radiology, but suspicion
of a malignant lesion was raised because of
the presence of double duct sign,1 and the
patient subsequently underwent pancreati-
coduodenectomy. Perioperatively, the pan-
creas was soft in texture and absent of
macroscopic tumor signs.FIGURE 1. A, Acinar-to-ductal metaplasia and a
7 (CK7), and the proliferationmarker Ki-67. Acin
Ki-67 proliferation rate. The AFL displays irregul
proliferation rate. Original magnification200.
invasive growth into the surrounding stroma (le
from normal exocrine pancreas parenchyma int
(bottom panel). Scale bars, 200 μm.
e60 www.pancreasjournal.comHistopathological evaluation revealed
KRAS-mutated PDAC with both a ductal
growth pattern and a low differentiated growth
pattern. The nonneoplastic pancreas was
marked by chronic atrophic pancreatitis with
extensive ADM positive for the ductal marker
cytokeratin 7 (Fig. 1A). The metaplastic
ductal epithelium consisted of inconspicu-
ous cuboidal cells with centrally placed ho-
mogenous nuclei and a low proliferative
activity indicated by less than 10% of Ki-
67–positive nuclei (Fig. 1A). Only in 1 single
acinus with ADM, pancreatic intraepithelial
neoplasia (PanIN) grade I was observed.
Several acini with metaplastic ductuli
displayed dysplastic changes of the epithe-
lium with pleomorphic hyperchromatic nu-
clei and a high proliferative activity with
more than 50% of Ki-67–positive nuclei in-
dicative ofAFLs (Fig. 1A). In addition, some
ducts showed back-to-back formations and
shift toward a cribriform growth pattern. In
1 acinus with AFL, an outgrowth of a dys-
plastic gland into the surrounding connec-
tive tissue was detected as a clear sign of
transition from AFL into infiltrative cancer
growth (Fig. 1B).DISCUSSION
Here, we present a case of PDAC that pre-
sents with extensive parenchymal atrophytypical flat lesions (AFLs) stained with hematoxy
ar-to-ductal metaplasia exhibits small CK7-positi
ar CK7-positive gland formations with highly ple
B, Overview over an acinus with AFL (right) and
ft). Original magnifications 50 and 400. Sca
o invasive ductal adenocarcinoma. Original ma
Pancrand ADMaswell as AFLs clearly progressing
into infiltrating cancer. This case report shows
that AFLs can progress to PDAC in human
and probably via a sequence from chronic
pancreatitis toward acinar atrophy andADM
(Fig. 1C).
Acinar-to-ductal metaplasia is defined
as the metaplastic transformation of pan-
creatic acinar cells into small intra-acinar
ductal CK7-positive cells. It can be induced
by stress and inflammation including pan-
creatitis, KRAS mutation, and epidermal
growth factor receptor activation.2 In mice
with KRAS mutation, ADM formation is an
early event in PDAC progression.3 In humans,
ADM is commonly found close to PanIN
lesions, but its role in PDAC progression
is not clear. Shi et al4 showed that ADM
near PanIN lesions often shares the same
KRASmutation, whereas isolated ADMwith-
out adjacent PanIN foci is of wild-typeKRAS.
The authors argue against acinar cells be-
ing the cell of origin in PDAC but that
ADM with KRAS mutations is more likely
a retrograde expansion of PanIN lesions.
An alternate interpretation is that ADMs that
acquire a KRASmutation develop into PanIN
lesions.2 The latter has been experimentally
supported in mouse models.5,6 We find it
unlikely that the present PDAC case arose
from PanIN lesions as only 1 low-grade
PanIN was observed in an ADM area.lin and eosin, the ductal marker cytokeratin
ve glands without dysplasia andwith a low
omorphic epithelial cells and a high Ki-67
amagnification showing the transition into
le bars, 200 μm. C, Theoretical progression
gnifications 50 (top panel) and 400
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from ADM via AFLs, which has been re-
cently shown in mouse models.7,8 The pres-
ence of AFLs has also been demonstrated
in human pancreas tissue, but without evi-
dence of AFLs progressing into invasive
carcinoma. Aichler et al8 reported the pres-
ence of AFLs in 3 familial pancreatic cancer
cases but could not find AFLs in any spo-
radic PDAC case. On the contrary, Morita
et al9 reviewed slides from 371 pancreatic
specimens with different sporadic PDAC
forms or benign lesions and identified AFLs
in 18 cases. However, these findings do not
clarify whether AFL is a precursor or only
a bystander. In this case report, there is a
clear progression from AFL into invasive
carcinoma, which strongly suggests that AFL
is the precursor lesion.
In summary, this case report shows for
the first time in humans that PDAC can arise
from AFLs. The prevalence of AFLs and its
pathophysiological role in pancreatic can-
cer need further investigation.
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on Patients With Operable
Pancreatic Cancer
To the Editor:T he emerging epidemiological data un-derscore the global impact of the
coronavirus disease 2019 (COVID-19)
pandemic. Since the first case was re-
ported in December 2019, in Wuhan,
China, the subsequent 4 months have seen
the virus spread to every continent. In tan-
dem with increasing infection rates, the
mortality associated with the infection
continues to rise, with over 90,000 deaths
reported worldwide with most authorities
recognizing that this does not reflect the
actual level of infection or mortality.1 Re-
search towards a vaccine and effective anti-
viral therapy is underway with much of
the effort in the Western world being
targeted towards manufacture of mechani-
cal ventilators to ensure timely treatment
of COVID-19 patients.2
The pandemic has, in addition, at least
had significant short- to medium-term effects
upon social activities, education, and the econ-
omy, although positive environmental effectsr Health, Inc.have been noted.3 The initial and on-going
media focus has predominantly and rightly
focused upon tracking the spread of the vi-
rus, its associated health indices, and the en-
suing economic downturn.4
With the focus continuing to be cen-
tered upon COVID-19 as a health emer-
gency, sparse attention is currently being
paid to the inevitable effects upon manage-
ment of other diseases during this time. The
rapidity of viral spread has forced a speedy
redistribution of resources in almost all
health care systems around the world with
priority being centered on ensuring intensive
care unit (ICU) capacity, which in some in-
stances has meant that operating rooms are
being used as additional ICU beds meaning
that anesthetic staff are being deployed to
care for these patients.
As a result, surgical services have
reduced their workload with most elective
surgery being postponed. The 4 surgical
Royal Colleges of the United Kingdom and
Ireland have released a joint consensus
statement providing guidance for emer-
gency general surgery, but the same has
not been published for cancer surgery.5 A
negative effect can be anticipated for patients
with almost all cancers but particularly
pancreatic cancer because most of these
patients will require preoperative anes-
thetic input and require ICU stay postoper-
atively. Several studies have demonstrated
the adverse impact of delay to surgery in
patients with pancreatic cancer.6 Sanjeevi
et al7 demonstrated that a waiting time
from diagnostic imaging to surgery of
more than 32 days doubles the rate of
irresectability in patients with pancreatic
ductal adenocarcinoma. Moreover, emerg-
ing data from the “fast track” pancreatic
surgery pathway suggests that this rapid
assessment process increases rates of cura-
tive resection.8
As a result of the COVID-19 pan-
demic, Kutikov et al9 have proposed guide-
lines for triaging patients with various
tumors, including pancreatic cancers. The
authors suggested that in cancers where
treatment delay may increase, the risk of
disease progression provision should be
made to offer immediate surgical interven-
tion in such patients who are younger than
70 years.9 Although pancreatic cancer
clearly falls into this remit on current fore-
casts of ICU bed occupancy, there will be
an inevitable delay in surgery for patients
with operable pancreatic cancer.
Patients with resectable pancreatic
cancers awaiting surgery for longer than
necessary may be offered chemotherapy
as a method of disease control and bridge
to surgery despite an evidence base. Ex-
trapolating data for this approach in resect-
able disease from those patients receivingwww.pancreasjournal.com e61
